GlaxoSmithKline Plc plans to double its research and development staff to 350 in the next few years.
The company currently employs 170 R&D staff in China.
Carol Zhu, head of operation management and alliances in GSK's China R&D unit said the drugmaker plans to boost that to 200 by the end of 2008 and to 350 within another year.
Zhu added that staff levels would remain fixed for three or four years after the increase.
The company will expand its facilities to acommodate further increases after that, she said.